Ashley Welch

All articles by Ashley Welch

• New data shows long-term benefits of avapritinib for people living with SM

  Updated data shows sustained clinical efficacy and tolerance of Ayvakit (avapritinib) treatment for systemic mastocytosis.

• Study finds rising incidence and cancer risk in US systemic mastocytosis cases

  New study reveals rising U.S. rates of systemic mastocytosis and increased risk of secondary cancers, especially in older adults.

• Researchers call for more individualized testing to diagnose systemic mastocytosis

  Relying on BST levels to diagnose SM doesn’t account for individual variability influenced by genetic and physiological factors.

• Current and future therapy options for systemic mastocytosis

  Several newly approved and experimental treatments have shown promise in the management of systemic mastocytosis.

• Genetic trait may heighten anaphylaxis risk for people with SM

  A genetic trait that increases risk of anaphylaxis is higher in people with SM. Identifying the trait early could mean better treatment.

• Targeted therapy brings rapid remission in child with SM-associated leukemia

  The targeted therapy drug gemtuzumab ozogamicin successfully treated a young boy with SM-AHN who did not respond to conventional therapies.

• New study highlights dangers fire ants pose to patients with systemic mastocytosis

  As fire ants spread to more areas, people with SM face a greater risk of severe allergic reactions from fire ant stings.

• New data reaffirms benefits of avapritinib to treat indolent and advanced SM

  Avapritinib treatment improves survival outcomes and symptom management in patients with SM, its maker reported.